MedTrace Logo

Oxulumis®, Suprachoroidal Drug Administration of Triesence® in Diabetic Macular Edema

NCT05172401 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2023-01-13

No results posted yet for this study

Summary

The purpose of this clinical investigation is to evaluate the safety and tolerability of using the Oxulumis® microcatheterization device to administer Triesence® to the suprachoroidal space in participants with DME.

Conditions

Interventions

DEVICE

Oxulumis® suprachoroidal microcatheterization administration of Triesence®

Suprachoroidally administered Triamcinolone acetonide (Triesence) 2.4mg/60µl

Sponsors & Collaborators

  • Oxular Limited

    lead INDUSTRY

Principal Investigators

  • Friedrich Asmus, MD · Oxular Limited

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-15
Primary Completion
2023-01-31
Completion
2023-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05172401 on ClinicalTrials.gov